Should I buy or sell Adlai Nortye stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adlai Nortye in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANL shares. View ANL analyst ratings or view top-rated stocks .

What is Adlai Nortye's stock price target for 2024?

1 Wall Street research analysts have issued 12 month price targets for Adlai Nortye's shares. Their ANL share price targets range from $30.00 to $30.00. On average, they expect the company's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 264.1% from the stock's current price. View analysts price targets for ANL or view top-rated stocks among Wall Street analysts .

How have ANL shares performed in 2024?

Adlai Nortye's stock was trading at $8.99 at the start of the year. Since then, ANL stock has decreased by 8.3% and is now trading at $8.24. View the best growth stocks for 2024 here .

When did Adlai Nortye IPO?

(ANL) raised $58 million in an IPO on Friday, September 29th 2023. The company issued 2,500,000 shares at $23.00 per share.

When does the company's lock-up period expire?

Adlai Nortye's lock-up period expires on Wednesday, March 27th. Adlai Nortye had issued 2,500,000 shares in its IPO on September 29th. The total size of the offering was $57,500,000 based on an initial share price of $23.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Adlai Nortye?

Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ANL

Adlai Nortye (ANL) Stock Price, News & Analysis

$8.24

-0.62 (-7.00%)

(As of 02/9/2024 08:55 PM ET)

Compare

Today's Range: $7.50
▼
$8.24
50-Day Range: $8.24
▼
$11.36
52-Week Range: $7.50
▼
$19.30

Volume: 1,700 shs
Average Volume: 1,129 shs
Market Capitalization: $304.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.00

Stock Analysis Analyst Forecasts Chart Competitors Financials SEC Filings Social Media

Get Adlai Nortye alerts:

About Adlai Nortye Stock (NASDAQ:ANL)

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.

ANL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANL Stock News Headlines

February 5, 2024 | finance.yahoo.com

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

February 5, 2024 | finance.yahoo.com

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

February 5, 2024 | finance.yahoo.com

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

February 5, 2024 | finance.yahoo.com

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

See More Headlines

Receive ANL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adlai Nortye and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 2/11/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ANL
Previous Symbol: NASDAQ:ANL
CUSIP: N/A
CIK: 1944552
Web: www.adlainortye.com
Phone: 848-230-7430
Fax: N/A
Employees: 130
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $30.00
High Stock Price Target: $30.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +264.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 36,900,000
Free Float: N/A
Market Cap: $304.06 million
Optionable: Not Optionable
Beta: N/A

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Yang Lu (Age 44)
CEO & Chairman
Ms. Wei Zhang (Age 33)
Chief Financial Officer
Dr. Kaiyang Tang (Age 60)
Senior VP & Global Head of Clinical Operations
Dr. Victoria Elizabeth Demby Ph.D. (Age 54)
Senior VP & Global Head of Regulatory Affairs

Key Competitors

View All Competitors

ANL Stock Analysis - Frequently Asked Questions

Should I buy or sell Adlai Nortye stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adlai Nortye in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANL shares.
View ANL analyst ratings or view top-rated stocks.
What is Adlai Nortye's stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price targets for Adlai Nortye's shares. Their ANL share price targets range from $30.00 to $30.00. On average, they expect the company's stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 264.1% from the stock's current price.
View analysts price targets for ANL or view top-rated stocks among Wall Street analysts.
How have ANL shares performed in 2024?: Adlai Nortye's stock was trading at $8.99 at the start of the year. Since then, ANL stock has decreased by 8.3% and is now trading at $8.24.
View the best growth stocks for 2024 here.
When did Adlai Nortye IPO?: (ANL) raised $58 million in an IPO on Friday, September 29th 2023. The company issued 2,500,000 shares at $23.00 per share.

When does the company's lock-up period expire?: Adlai Nortye's lock-up period expires on Wednesday, March 27th. Adlai Nortye had issued 2,500,000 shares in its IPO on September 29th. The total size of the offering was $57,500,000 based on an initial share price of $23.00. After the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.
How do I buy shares of Adlai Nortye?: Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANL) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adlai Nortye (ANL) Stock Price, News & Analysis

About Adlai Nortye Stock (NASDAQ:ANL)

ANL Stock Price History

ANL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ANL Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info